Cytomed Therapeutics LTD

Chee Kong Choo, a Director and 10% owner of CytoMed Therapeutics Ltd, purchased 200,000 shares of common stock on July 14, 2026 for $1.50 per share.

Chee Kong Choo, a Director and 10% owner of CytoMed Therapeutics Ltd, reported multiple transactions in common stock on July 14, 2026.

CytoMed Therapeutics Ltd director Chee Kong Choo reported transactions involving ordinary shares, including acquisitions and disposals.

Choo Chee Kong, Chairman and Director of CytoMed Therapeutics Ltd, has amended his Schedule 13D filing to report beneficial ownership of 2,899,746 Ordinary Shares, representing 24.30% of the company's outstanding stock.

CytoMed Therapeutics Limited's Chairman, Choo Chee Kong, has increased his beneficial ownership to 22.05% of the company's ordinary shares.

CytoMed Therapeutics Ltd's Chairman and Director, Choo Chee Kong, has filed an amended Schedule 13D, revealing a reduction in his beneficial ownership to 23.17% following a gift of 715,000 ordinary shares.

mDR Limited has filed an amendment to its Schedule 13G, disclosing a beneficial ownership of 11.33% in CytoMed Therapeutics Ltd, following a minor share sale.

28 Consultants Ltd has disclosed a beneficial ownership of 7.62% in CytoMed Therapeutics Ltd, holding 880,313 Ordinary Shares.